Skip to content
All articles

Retrospective cohort study of impact of computed tomography screening on small cell lung cancer stage shift and survival

Dr. Chi-Fu Jeffrey Yang
Dr. Chi-Fu Jeffrey Yang

Lung cancer screening with low-dose computed tomography (LDCT) has been shown to identify lung cancer at earlier stages and to significantly reduced lung cancer mortality. However, the benefit of LDCT screening for small cell lung cancer (SCLC) is unclear. A retrospective cohort study investigated characteristics and outcomes of SCLC diagnosed after lung cancer screening using a large database of Medicare beneficiaries. Patients in the US aged 65 to 78 years who were diagnosed with SCLC from 2015 to 2021 were identified for analysis, with follow-up data through 2022. Patients who underwent one or more LDCT lung cancer screening examinations during the 12 months preceding their SCLC diagnosis were included in the screened group; all other patients were included in the unscreened group. The primary outcomes were stage at SCLC diagnosis and overall survival after SCLC diagnosis. A total of 17 099 patients (52.6% female) were included, of which 949 (5.5%) were included in the screened group. When compared with patients in the unscreened group, patients in the screened group were significantly less likely to be diagnosed with distant disease (44.2% versus 70.4%). Patients in the screened group also had significantly better overall survival (at 3 years 28.0% versus 10.6%; p<0.001). Both findings were consistent in propensity score-matched analysis. The authors conclude that results of this cohort study of Medicare beneficiaries diagnosed with SCLC suggest that receipt of LDCT lung cancer screening was associated with a shift toward earlier-stage SCLC at diagnosis and improved overall survival.

Original publicationjamanetwork.com
Read the publication